君实生物(01877)III期肝癌新药JS207联合JS007完成首例患者给药

公告速递
Oct 29

2026年10月30日,君实生物(01877)发布公告称,公司自主研发的重组人源化抗PD-1和VEGF双特异性抗体JS207联合抗CTLA-4单克隆抗体JS007,用于一线治疗晚期肝细胞癌的多中心、随机、对照、开放III期临床研究(研究代号:JS207-017-III-HCC,NCT07823348)已完成首例患者给药。该研究计划入组560例受试者,主要终点为无进展生存期(PFS)和总生存期(OS)。

JS207为君实生物自主研发的重组人源化抗PD-1和VEGF双特异性抗体,可同时高亲和力结合PD-1和VEGFA;JS007为公司自主研发的重组人源化抗CTLA-4单克隆抗体。

在2026年欧洲肿瘤内科学会(ESMO)公布的Ⅱ期研究(JS207-006-II-HCC)结果显示,36例患者接受JS207联合JS007治疗,其中34例可评估疗效的患者客观缓解率(ORR)为44.1%,疾病控制率(DCR)为85.3%,中位PFS尚未达到,6个月PFS率为67%。

公司提示,医药产品研发及审批流程存在不确定性,上述项目仍处于临床试验阶段,敬请投资者注意投资风险。君实生物表示,将按照相关规定及时披露项目进展信息。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10